137 related articles for article (PubMed ID: 15262189)
1. Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo.
Schneider JG; von Eynatten M; Parhofer KG; Volkmer JE; Schiekofer S; Hamann A; Nawroth PP; Dugi KA
Atherosclerosis; 2004 Aug; 175(2):325-31. PubMed ID: 15262189
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
3. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects.
Parhofer KG; Barrett PH; Schwandt P
J Clin Endocrinol Metab; 2000 Nov; 85(11):4224-30. PubMed ID: 11095458
[TBL] [Abstract][Full Text] [Related]
5. The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
Black RN; Ennis CN; Young IS; Hunter SJ; Atkinson AB; Bell PM
J Diabetes Complications; 2014; 28(3):323-7. PubMed ID: 24560135
[TBL] [Abstract][Full Text] [Related]
6. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
Diabetes Atorvastin Lipid Intervention (DALI) Study Group
Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
[TBL] [Abstract][Full Text] [Related]
7. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
8. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
9. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
10. Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes.
Bach-Ngohou K; Ouguerram K; Frénais R; Maugère P; Ripolles-Piquer B; Zaïr Y; Krempf M; Bard JM
J Pharmacol Exp Ther; 2005 Oct; 315(1):363-9. PubMed ID: 16014756
[TBL] [Abstract][Full Text] [Related]
11. The effect of atorvastatin on serum lipoproteins in acromegaly.
Mishra M; Durrington P; Mackness M; Siddals KW; Kaushal K; Davies R; Gibson M; Ray DW
Clin Endocrinol (Oxf); 2005 Jun; 62(6):650-5. PubMed ID: 15943824
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin and pitavastatin enhance lipoprotein lipase production in L6 skeletal muscle cells through activation of adenosine monophosphate-activated protein kinase.
Ohira M; Endo K; Saiki A; Miyashita Y; Terai K; Murano T; Watanabe F; Tatsuno I; Shirai K
Metabolism; 2012 Oct; 61(10):1452-60. PubMed ID: 22520230
[TBL] [Abstract][Full Text] [Related]
13. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
[TBL] [Abstract][Full Text] [Related]
14. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
Huptas S; Geiss HC; Otto C; Parhofer KG
Am J Cardiol; 2006 Jul; 98(1):66-9. PubMed ID: 16784923
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
16. Effect of atorvastatin on type 2 diabetic dyslipidemia.
Save V; Patil N; Moulik N; Rajadhyaksha G
J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):262-70. PubMed ID: 17220473
[TBL] [Abstract][Full Text] [Related]
17. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
18. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
19. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?
Battula SB; Fitzsimons O; Moreno S; Owens D; Collins P; Johnson A; Tomkin GH
Metabolism; 2000 Aug; 49(8):1049-54. PubMed ID: 10954025
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical modifications induced by statins therapy on human erythrocytes membranes.
Broncel M; Bała A; Koter-Michalak M; Duchnowicz P; Wojsznis W; Chojnowska-Jezierska J
Wiad Lek; 2007; 60(7-8):321-8. PubMed ID: 18175550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]